A look at the most quoted research papers on optic pathway glioma
Original title: Bibliometric mapping of the 100 most-cited publications on optic nerve and optic pathway glioma: A cross-sectional bibliometric analysis.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This looks across many earlier studies rather than running a new one.
This study looked at research papers, not at people or treatments.
The short version
This study looked at research papers about optic pathway glioma: A tumor that starts in the glial cells, the support cells of the brain and spinal cord. Gliomas are given a grade from 1 to 4 describing how the tumor is expected to behave. See the glossary, not at patients.
What was studied. Researchers searched a large science database for papers on optic pathway glioma: A tumor that starts in the glial cells, the support cells of the brain and spinal cord. Gliomas are given a grade from 1 to 4 describing how the tumor is expected to behave. See the glossary. They kept the 100 papers that other papers quoted the most.
What they found. The 100 papers came out between 2000 and 2021. Other papers quoted them 9305 times in all. First authors came from 17 countries, and 53 were from the United States.
What this means, and what it doesn't
What it could mean: It shows where scientists have aimed their attention over time. Interest moved toward the biology of NF1 tumors and better scans. Most of this work came from a few centers in North America.
What it doesn't mean: This is not a treatment and not a cure. No drug, scan, or surgery was tested in people here. The authors only counted how often papers were quoted. They say plainly that this does not show which studies mattered most or were best done. Nothing here changes the care your doctor can offer today.
Source: PubMed, October 2, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.